Camber Pharmaceuticals, Inc.

05/16/2024

Camber Pharmaceuticals is thrilled to announce the addition of Rufinamide Oral Suspension to its product line. Following the launch of Rufinamide Tablets in 2021, this new addition completes the Rufinamide product family.

Rufinamide Oral Suspension is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.

Rufinamide Oral Suspension 40 mg/mL is available in a 460 mL bottle with child-resistant closure along with two calibrated oral dosing syringes and an adapter.

04/26/2024

Camber Pharmaceuticals is thrilled to announce the addition of Aripiprazole Oral Solution to its product line, complementing the existing product family that included Aripiprazole Tablets. Camber initially launched Aripiprazole Tablets in 2015, as one of the first generic alternatives to Abilify®, significantly expanding patient access to this life-changing medication.

Aripiprazole Oral Solution is indicated for the treatment of:
• Schizophrenia
• Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder
• Irritability Associated with Autistic Disorder
• Treatment of Tourette’s Disorder

Aripiprazole Oral Solution 1 mg/mL is available in 150 mL child-resistant bottles along with a calibrated oral dosing cup.

To learn more about Aripiprazole Oral Solution, please visit https://www.camberpharma.com/aripiprazole-oral-sol

https://conta.cc/3wl2phT

04/17/2024

Camber Pharmaceuticals is excited to introduce Fesoterodine Fumarate Extended-Release Tablets.

According to the Cleveland Clinic, approximately 33 million Americans struggle with overactive bladders, impacting about 30% of adult males and 40% of adult females nationwide.

Fesoterodine Fumarate ER Tablets are indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency.

Fesoterodine Fumarate ER Tablets are available in 30 count bottles in 4 mg and 8 mg strengths.

To learn more about Fesoterodine Fumarate Extended- Release Tablets, please visit https://www.camberpharma.com/fesoterodine-fumarate-er

https://conta.cc/3xDiakP

New Product Launch   Camber Pharmaceuticals Launches Generic Toviaz® Piscataway, NJ, April 17, 2024- Camber Pharmaceuticals is excited to introduce Fesoterodine Fumarate Extended-Release Tablets. Acco

04/09/2024

Camber Pharmaceuticals is pleased to announce the addition of Pantoprazole Sodium for Delayed-Release Oral Suspension to its current portfolio.

Pantoprazole Sodium for Delayed-Release Oral Suspension is indicated for:
* Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) in adults and pediatric patients five years of age and older.
* Maintenance of Healing of Erosive Esophagitis and Reduction in Relapse Rates of Daytime and Nighttime Heartburn Symptoms in adult patients with GERD.
* Long- Term Treatment of Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome.

Pantoprazole Sodium for Delayed-Release 40 mg Oral Suspension is available in cartons of 30 unit dose packets.

To find out more about Pantoprazole Sodium for Delayed-Release Oral Suspension, please visit https://www.camberpharma.com/pantoprazole-dr-oral-susp

https://conta.cc/3U8WZ2O

New Product Launch   Camber Pharmaceuticals Launches Generic Protonix® Piscataway, NJ, April 9, 2024–Camber Pharmaceuticals is pleased to announce the addition of Pantoprazole Sodium for Delayed-Relea

04/04/2024

Camber Pharmaceuticals is pleased to announce the addition of Levonorgestrel and Ethinyl Estradiol Tablets USP to its current portfolio.

Levonorgestrel and Ethinyl Estradiol Tablets USP are indicated for the prevention of pregnancy in women who elect to use oral contraceptives.

Levonorgestrel and Ethinyl Estradiol Tablets USP (0.1 mg/0.02 mg) is available in boxes of 3 blister packs of 28 tablets/packet.

To find out more about Levonorgestrel and Ethinyl Estradiol Tablets USP, please visit https://www.camberpharma.com/levonorgestrel-ee

https://conta.cc/3xlZohv

New Product Launch   Camber Pharmaceuticals Launches Generic Alesse® Piscataway, NJ, April 4, 2024–Camber Pharmaceuticals is pleased to announce the addition of Levonorgestrel and Ethinyl Estradiol Ta

04/02/2024

Camber Pharmaceuticals is pleased to announce the addition of Allopurinol Tablets, USP to its current portfolio.

Allopurinol Tablets, USP are indicated for:

1) the management of patients with signs and symptoms of primary or secondary gout.

2) the management of patients with conditions requiring therapies which cause elevations of serum and urinary uric acid levels.

3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds specific thresholds.

Camber's Allopurinol Tablets, USP 100 mg and 300 mg are available in 100, 500 and 1000 count bottles.

To find out more about Camber's Allopurinol Tablets, USP please visit https://www.camberpharma.com/allopurinol

https://conta.cc/3xhrbjb

New Product Launch   Camber Pharmaceuticals Launches Generic Zyloprim® Piscataway, NJ, April 2, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Allopurinol Tablets, USP to its cur

03/20/2024

Camber Pharmaceuticals is pleased to announce the addition of Theophylline Extended-Release Tablets to its current portfolio.

Theophylline Extended-Release Tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases.

Theophylline Extended-Release Tablets are available in 300 mg and 450 mg strengths, both in 100 count bottles.

To find out more about Theophylline Extended-Release Tablets, please visit https://www.camberpharma.com/theophylline-er

https://conta.cc/496uaYO

New Product Launch   Camber Pharmaceuticals Launches Theophylline Extended-Release Tablets Piscataway, NJ, March 20, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Theophylline E

03/18/2024

Camber Pharmaceuticals is pleased to announce the addition of Gabapentin Tablets (generic for Gralise®) to its current portfolio. Camber already offers Gabapentin Tablets and Capsules (generic for Neurontin®). Generics for Gralise® and Neurontin® are not interchangeable.

Gabapentin Tablets (generic for Gralise®) are indicated for the management of Postherpetic Neuralgia (PHN).

Gabapentin Tablets (generic for Gralise®) 300 mg and 600 mg are available in 90 count bottles.

To find out more about Gabapentin Tablets, please visit https://www.camberpharma.com/gabapentintablets-gralise

https://conta.cc/4cj7qrA

New Product Launch   Camber Pharmaceuticals Launches Generic Gralise® Piscataway, NJ, March 18, 2024– Camber Pharmaceuticals is pleased to announce the addition of Gabapentin Tablets (generic for Gral

03/08/2024

Camber Pharmaceuticals is pleased to announce the addition of Icosapent Ethyl Capsules to its current portfolio.

Icosapent Ethyl Capsules are an ethyl ester of eicosapentaenoic acid (EPA) indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.

Icosapent Ethyl Capsules are available in:
0.5 gram – 240 count bottles
1 gram – 120 count bottles

To find out more about Icosapent Ethyl Capsule, please visit https://www.camberpharma.com/icosapent

https://conta.cc/3V7Also

New Product Launch   Camber Pharmaceuticals Launches Generic Vascepa® Piscataway, NJ, March 8, 2024–Camber Pharmaceuticals is pleased to announce the addition of Icosapent Ethyl Capsules to its curren

02/29/2024

Piscataway, NJ, February 29, 2024–Camber Pharmaceuticals is pleased to announce the addition of Oxcarbazepine Oral Suspension, USP to its current portfolio.

Oxcarbazepine Oral Suspension, USP is indicated for:

*Adults as monotherapy or adjunctive therapy in the treatment of partial-onset seizures.
*Pediatrics as monotherapy in the treatment of partial-onset seizures in children 4 to 16 years of age, and as adjunctive therapy in the treatment of partial-onset seizures in children 2 to 16 years of age.

Oxcarbazepine Oral Suspension, USP 300 mg/5 mL is available in 250 mL bottles.

https://conta.cc/3uQcUcs

New Product Launch   Camber Pharmaceuticals Launches Generic Trileptal® Piscataway, NJ, February 29, 2024–Camber Pharmaceuticals is pleased to announce the addition of Oxcarbazepine Oral Suspension, U

11/27/2023

Camber Pharmaceuticals is pleased to announce the addition of Famotidine Powder for Oral Suspension, USP to its current portfolio.

Famotidine Powder for Oral Suspension, USP is indicated:

In adults for the treatment of:

*active duodenal ulcer (DU).
*active gastric ulcer (GU).
*symptomatic nonerosive gastroesophageal reflux disease (GERD).
*erosive esophagitis due to GERD, diagnosed by biopsy.
*treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias).
*reduction of the risk of DU recurrence.

In pediatric patients 1 year of age and older for the treatment of:

*peptic ulcer disease.
*GERD with or without esophagitis and ulcerations.

In pediatric patients from birth to less than 1 year of age for the treatment of:

*GERD.

Famotidine 40 mg/5 mL Powder for Oral Suspension, USP is available in a bottle to make 50 mL when reconstituted as directed.

https://conta.cc/3QPBzEM

New Product Launch   Camber Pharmaceuticals Launches Generic Pepcid® Piscataway, NJ, November 27, 2023–Camber Pharmaceuticals is pleased to announce the addition of Famotidine Powder for Oral Suspensi

11/17/2023

Camber Pharmaceuticals is pleased to announce the addition of Bupropion HCl ER Tablets, USP (SR) to its current portfolio.

Bupropion HCl ER Tablets, USP (SR) are an aminoketone antidepressant, indicated for the treatment of major depressive disorder.

Bupropion HCl ER Tablets, USP (SR) are available in 100 and 150 mg strengths in 60, 100 and 500 count bottles as well as 200 mg in 60 and 100 count bottles.

https://conta.cc/3QDJRQa

New Product Launch   Camber Pharmaceuticals Launches Generic Wellbutrin SR® Piscataway, NJ, November 17, 2023–Camber Pharmaceuticals is pleased to announce the addition of Bupropion HCl ER Tablets, US

10/18/2023

Camber is pleased to add Darunavir Tablets to its portfolio. Darunavir Tablets are a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult and pediatric patients 3 years of age and older.



https://conta.cc/3S7fm7w

New Product Launch   Camber Pharmaceuticals Launches Generic Prezista® Piscataway, NJ, October 18, 2023–Camber Pharmaceuticals is pleased to announce the addition of Darunavir Tablets to its current p

08/24/2023

Camber Pharmaceuticals is pleased to announce the addition of Ezetimibe Tablets, USP to its current portfolio.

Ezetimibe Tablets, USP are an inhibitor of intestinal cholesterol (and related phytosterol) absorption indicated as an adjunct to diet to:

* Reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin)
* Reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate
* Reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), in combination with atorvastatin or simvastatin
* Reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia (phytosterolemia)

Ezetimibe 10 mg Tablets are available in 30 and 90 count bottles.

To find out more about Ezetimibe Tablets, USP please visit www.camberpharma.com.

https://conta.cc/3ORE48Q

New Product Launch   Camber Pharmaceuticals Launches Generic Zetia® Piscataway, NJ, August 24, 2023–Camber Pharmaceuticals is pleased to announce the addition of Ezetimibe Tablets, USP to its current

08/08/2023

Camber Pharmaceuticals is pleased to announce the addition of Deferasirox Oral Granules to its current portfolio.

Deferasirox Oral Granules are indicated for the treatment of chronic iron overload (1) due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older, and (2) in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes exhibiting elevated liver and serum iron concentrations.

Deferasirox Oral Granules 180 mg and 360 mg sachets are available in 30 count cartons.

To find out more about Deferasirox Oral Granules please visit www.camberpharma.com.

https://conta.cc/3OMaxhM

New Product Launch   Camber Pharmaceuticals Launches Generic Jadenu® Sprinkle Piscataway, NJ, August 8, 2023–Camber Pharmaceuticals is pleased to announce the addition of Deferasirox Oral Granules to

08/07/2023

Camber Pharmaceuticals is pleased to announce the addition of Ketorolac Tromethamine Tablets, USP to its current portfolio.

Ketorolac Tromethamine Tablets are indicated for the short-term (up to 5 days in adults) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM dosing of ketorolac tromethamine, and Ketorolac Tromethamine Tablets are to be used only as continuation treatment, if necessary.

Ketorolac Tromethamine, USP 10 mg are available in 100 count bottles.

To find out more about Ketorolac Tromethamine Tablets, USP please visit www.camberpharma.com

https://conta.cc/45k3gLU

New Product Launch   Camber Pharmaceuticals Launches Generic Toradol® Piscataway, NJ, August 7, 2023–Camber Pharmaceuticals is pleased to announce the addition of Ketorolac Tromethamine Tablets, USP t

08/01/2023

Camber Pharmaceuticals is pleased to announce the addition of Ibuprofen and Famotidine Tablets to its current portfolio.

Ibuprofen and Famotidine Tablets, a combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the histamine H2- receptor antagonist famotidine, is indicated for (1) the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and (2) to decrease the risk of developing upper gastrointestinal ulcers, in patients who are taking ibuprofen for those indications.

Ibuprofen and Famotidine 800 mg/26.6mg Tablets are available in 90 count bottles
https://conta.cc/3rL6Fog

New Product Launch   Camber Pharmaceuticals Launches Generic Duexis® Piscataway, NJ, August 1, 2023–Camber Pharmaceuticals is pleased to announce the addition of Ibuprofen and Famotidine Tablets to it

07/27/2023

Camber Pharmaceuticals is pleased to announce the addition of Daptomycin for Injection in both 350 mg and 500 mg strengths to its current portfolio.

Daptomcycin for Injection is a lipopeptide antibacterial indicated for the treatment of complicated skin and skin structure infections (cSSSI) in adult patients and pediatric patients (1 to 17 years of age).

Daptomcycin for Injection is available in 350 mg and 500 mg Single- Dose Vials.

To find out more about Daptomcycin for Injection please visit www.camberpharma.com

https://conta.cc/3OcrWPj

06/06/2023

Camber Pharmaceuticals is pleased to announce the addition of Mexiletine Hydrochloride Capsules, USP to its current portfolio.

Mexiletine Hydrochloride Capsules, USP are for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

Mexiletine Hydrochloride Capsules, USP are available in 150, 200 and 250 mg strengths in 100 count bottles.

To find out more about Mexiletine Hydrochloride Capsules, USP please visit www.camberpharma.com

Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.

https://conta.cc/42r38Ig

New Product Launch   Camber Pharmaceuticals Launches Generic Mexitil® Piscataway, NJ, June 6, 2023–Camber Pharmaceuticals is pleased to announce the addition of Mexiletine Hydrochloride Capsules, USP

05/08/2023

Camber Pharmaceuticals is pleased to announce the addition of Trientine Hydrochloride Capsules, USP to its current portfolio.

Trientine Hydrochloride Capsules, USP are indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.

Trientine Hydrochloride Capsules, USP are available in 250 mg strength in 100 count bottles.

To find out more about Trientine Hydrochloride Capsules, USP please visit www.camberpharma.com

https://conta.cc/3B3ucT1

05/03/2023

Camber Pharmaceuticals is pleased to announce the addition of Promethazine HCI Suppositories, USP to its current portfolio.

Promethazine HCI Suppositories, USP are used to treat allergy symptoms such as itching, runny nose, sneezing, itchy or watery eyes, hives, and itchy skin rashes. It also prevents motion sickness and treats nausea and vomiting or pain after surgery. It is also used as a sedative or sleep aid.

Promethazine HCI Suppositories, USP are available in 12.5 and 25 mg strengths in 12 count boxes.

To find out more about Promethazine HCI Suppositories, USP please visit https://www.camberpharma.com

https://conta.cc/3p4QSPR

New Product Launch   Camber Pharmaceuticals Launches Generic Phenergan® Piscataway, NJ, May 3, 2023–Camber Pharmaceuticals is pleased to announce the addition of Promethazine HCI Suppositories, USP to

04/26/2023

Camber Pharmaceuticals is pleased to announce the addition of Zileuton ER Tablets to its current portfolio.

Zileuton ER Tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Zileuton ER Tablets are not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with Zileuton ER Tablets can be continued during acute exacerbations of asthma.

Zileuton ER Tablets are available in 600 mg strength in 120 count bottles.

To find out more about Zileuton ER Tablets please visit www.camberpharma.com

https://conta.cc/4493DZV

New Product Launch   Camber Pharmaceuticals Launches Generic Zyflo CR® Piscataway, NJ, April 26, 2023–Camber Pharmaceuticals is pleased to announce the addition of Zileuton ER Tablets to its current p

04/21/2023

Camber Pharmaceuticals is pleased to announce the addition of Roflumilast 250 mcg Tablets to its current portfolio.

Roflumilast Tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD, associated with chronic bronchitis and a history of exacerbations.
Roflumilast 250 mcg Tablets are available in 20 and 28 unit-dose cartons.

Roflumilast Tablets are also available in 500 mcg strength in 30 and 90 count bottles.
To find out more about Roflumilast Tablets please visit www.camberpharma.com

Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.

https://conta.cc/3UZ5rR5

03/31/2023

Camber Pharmaceuticals is pleased to announce the addition of Aminocaproic Acid Oral Solution, USP to its current portfolio.

Aminocaproic Acid Oral Solution is useful in enhancing hemostasis when fibrinolysis contributes to bleeding.

Our raspberry-flavored Aminocaproic Acid Oral Solution 0.25 g/mL is available in 8 Fl. Oz. bottles

To find out more about Aminocaproic Acid Oral Solution please visit www.camberpharma.com

https://conta.cc/3G3aSYY

New Product Launch   Camber Pharmaceuticals Launches Generic Amicar® Piscataway, NJ, March 31, 2023–Camber Pharmaceuticals is pleased to announce the addition of Aminocaproic Acid Oral Solution, USP t

03/21/2023

Camber Pharmaceuticals is pleased to announce the addition of Levothyroxine Sodium Tablets, USP to its current portfolio.

Levothyroxine Sodium Tablets, USP are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism, and as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

Levothyroxine Sodium Tablets, USP are available in 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, and 300 mcg strengths and supplied in 90 and 1000 count bottles.

To find out more about Levothyroxine Sodium Tablets, USP please visit www.camberpharma.com

https://conta.cc/42v01Al

  Camber Pharmaceuticals Launches Generic Thyro-Tabs® Piscataway, NJ, March 21, 2023–Camber Pharmaceuticals is pleased to announce the addition of Levothyroxine Sodium Tablets, USP to its current port

03/13/2023

Camber Pharmaceuticals is pleased to announce the addition of Teriflunomide Tablets to its current portfolio.

Teriflunomide Tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Teriflunomide Tablets are available in 7 and 14 mg strengths and supplied in 30 count bottles.

To find out more about Teriflunomide Tablets please visit www.camberpharma.com

https://conta.cc/3LkS8Y5

  Camber Pharmaceuticals Launches Generic Aubagio® Piscataway, NJ, March 13, 2023–Camber Pharmaceuticals is pleased to announce the addition of Teriflunomide Tablets to its current portfolio.

03/09/2023

Camber Pharmaceuticals is pleased to announce the addition of Linezolid for Oral Suspension to its current portfolio.

Linezolid for Oral Suspension is indicated for the treatment of nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and resistant isolates) or Streptococcus pneumoniae.

Linezolid for Oral Suspension is available in a 100 mg/5 mL strength and supplied in a 150 mL bottle.

To find out more about Linezolid for Oral Suspension please visit www.camberpharma.com

https://conta.cc/3Fd6Cp4

  Camber Pharmaceuticals Launches Generic Zyvox® Piscataway, NJ, March 9, 2023–Camber Pharmaceuticals is pleased to announce the addition of Linezolid for Oral Suspension to its current portfolio.

03/03/2023

Camber Pharmaceuticals is pleased to announce the addition of Ranolazine ER Tablets to its current portfolio.

Ranolazine ER Tablets is a prescription medicine used to treat angina that keeps coming back (chronic angina).

Ranolazine ER Tablets may be used with other medicines that are used for heart problems and blood pressure control.

Ranolazine ER Tablets are available in 500 and 1000 mg strengths and supplied in 60 count bottles.

To find out more about Ranolazine ER Tablets please visit www.camberpharma.com

https://conta.cc/3ya1ONr

  Camber Pharmaceuticals Launches Generic Ranexa® Piscataway, NJ, March 3, 2023–Camber Pharmaceuticals is pleased to announce the addition of Ranolazine ER Tablets to its current portfolio.

03/01/2023

Camber Pharmaceuticals is pleased to announce the addition of Valganciclovir for Oral Solution to its current portfolio.

Valganciclovir for Oral Solution is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for:

Adult Patients:
• Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).
• Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk.
Pediatric Patients:
• Prevention of CMV disease in kidney and heart transplant patients at high risk.

Valganciclovir for Oral Solution 50 mg/mL is available in 100mL bottles.

To find out more about Valganciclovir for Oral Solution please visit www.camberpharma.com

https://conta.cc/3ZAiz05

  Camber Pharmaceuticals Launches Generic Valcyte® Piscataway, NJ, March 1, 2023–Camber Pharmaceuticals is pleased to announce the addition of Valganciclovir for Oral Solution to its current portfolio

01/11/2023

Camber Pharmaceuticals is pleased to announce the addition of Diclofenac Potassium for Oral Solution to its current portfolio.

Diclofenac Potassium for Oral Solution is a non-steroidal anti-inflammatory drug (NSAID) indicated for the acute treatment of migraine attacks with or without aura, in adults 18 years of age or older.

Diclofenac Potassium for Oral Solution is available in 50 mg strength and supplied as a box of 9 individual packets.

To find out more about Diclofenac Potassium for Oral Solution please visit www.camberpharma.com

https://conta.cc/3IY9fhx

  Camber Pharmaceuticals Launches Generic Cambia® Piscataway, NJ, January 11, 2023–Camber Pharmaceuticals is pleased to announce the addition of Diclofenac Potassium for Oral Solution to its current p